Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b/3 Trial of SJP-002C.

Trial Profile

A Phase 2b/3 Trial of SJP-002C.

Status: Not stated
Phase of Trial: Phase II/III

Latest Information Update: 07 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SJP-002C (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 07 Nov 2025 New trial record
  • 26 Sep 2025 According to Sen Jam Pharmaceutical media release, company announced the successful completion of the final development submission batches of SJP-002C and finalized the Chemistry, Manufacturing, and Controls (CMC) package, meeting FDA standards and positioning the program for Phase 2b/3 clinical trials.
  • 26 Sep 2025 According to Sen Jam Pharmaceutical media release, company is now positioned to begin the next phase of clinical testing.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top